This is Post 3 of a 5-part series on the drugs used to manage type 2 diabetes and metabolic disease. Post 1 covered metformin. Posts 2A and 2B covered SGLT2 inhibitors. Now we arrive at the class everyone is actually asking me about.
If you’ve been anywhere near a conversation about weight in the last two years, you already know the names. Ozempic. Wegovy. Mounjaro. Zepbound. They’ve gone from a diabetes drug your endocrinologist mentioned to a cultural phenomenon with a waiting list.
Here’s my problem with almost every take on these drugs: it’s either “miracle” or “cheating.” Neither is honest. So let me do what I did with the SGLT2 inhibitors — give you the actual accounting. What these drugs do, what the evidence shows, and where the real coaching conversation lives.
This post is the case for them. It’s substantial, and I’m not going to soft-pedal it. The costs — the muscle loss, the rebound, the price tag, the part where the drug doesn’t fix the thing that got you here — those get their own post next. But you can’t weigh the costs honestly until you understand how good the upside actually is. So that’s where we start.
What these drugs actually are
GLP-1 stands for glucagon-like peptide-1. It’s a hormone your gut already makes, in small amounts, every time you eat. It does several useful things: it tells your pancreas to release insulin (but only when blood sugar is actually elevated), it slows how fast your stomach empties, it suppresses glucagon (the hormone that tells your liver to dump sugar), and — this is the big one — it signals your brain that you’re full.
The drugs are synthetic versions of that hormone, engineered to last far longer than the few minutes your natural GLP-1 survives. A once-weekly injection keeps that “I’m satisfied, I don’t need the rest of this” signal running more or less continuously.
That’s the mechanism. It’s not speeding up your metabolism. It’s not blocking fat absorption. It’s turning down appetite and smoothing out blood sugar. The weight loss is largely downstream of eating less because you’re genuinely less hungry.
There are two drugs that dominate the conversation, and one distinction between them that matters:
- Semaglutide — sold as Ozempic (for type 2 diabetes) and Wegovy (for weight management). A pure GLP-1 receptor agonist.
- Tirzepatide — sold as Mounjaro (for diabetes) and Zepbound (for weight management). This one hits two receptors: GLP-1 and GIP, a second incretin hormone. That dual action appears to add a modest edge on both appetite and energy expenditure.
The older members of the class — liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta) — still get prescribed, but they’ve largely been eclipsed by the once-weekly heavyweights. And there’s a triple agonist, retatrutide, still in trials, that adds a third target (glucagon) and is posting even larger numbers. That’s a “what’s coming” story, not a “what you can get” story, so I’ll leave it there for now.
The weight loss data is not hype
Let me be precise, because the numbers get thrown around loosely.
For semaglutide, the STEP trial program in non-diabetic adults with obesity showed roughly 15% average body weight reduction over 68 weeks. For tirzepatide, the SURMOUNT-1 trial (2,539 adults with obesity or overweight, 72 weeks) showed average reductions of 16.0%, 21.4%, and 22.5% at the 5 mg, 10 mg, and 15 mg doses respectively — versus 2.4% on placebo. At the top dose, roughly 4 in 10 participants lost at least a quarter of their body weight.
And in December 2024, we got the head-to-head. SURMOUNT-5 (751 adults, 72 weeks) pitted tirzepatide directly against semaglutide: 20.2% average weight loss for tirzepatide versus 13.7% for semaglutide. Tirzepatide won on essentially every weight endpoint.
I want to sit on one detail from SURMOUNT-1 that most coverage skips, because it’s the hinge of the entire series. A DXA body-composition substudy looked at what the lost weight was actually made of. The answer: roughly 75% of it was fat and about 25% was lean mass (muscle and other non-fat tissue). To be fair to the drug, the researchers noted that this proportion is similar to what you’d see with almost any large weight loss — it isn’t uniquely muscle-wasting. But here’s why I won’t let it slide: on a diet you feel hungry, which nudges you to prioritize protein and hold onto strength. On a GLP-1, the appetite signal is gone, and if you’re not deliberate, protein intake and training tend to fall away exactly when your muscle needs defending. That’s not a reason to dismiss the drug. It’s a reason to train and eat like your muscle depends on it — because a quarter of what you lose otherwise comes from it. Hold that thought. It’s the spine of Post 4.
This is where it stops being “just” a weight loss drug
If GLP-1s only drove weight loss, they’d be interesting. What makes them a genuinely different tier of drug is what showed up in the hard-outcome trials — the ones that count heart attacks, kidney failure, and deaths, not pounds.
Cardiovascular protection
The cardiovascular story didn’t start with weight loss. Back in 2016, the SUSTAIN-6 trial showed semaglutide reduced major cardiovascular events in people with type 2 diabetes. The landmark that changed the wider conversation, though, was SELECT. It enrolled 17,604 adults who had established cardiovascular disease and were overweight or obese — but did not have diabetes — and ran them on semaglutide 2.4 mg or placebo. The result: a 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke; hazard ratio 0.80, p<0.001). In absolute terms, the event rate dropped from 8.0% to 6.5%.
Why that matters so much: it’s the first time a weight-management drug was shown, in a rigorous randomized trial, to reduce cardiovascular events in people without diabetes. And a prespecified analysis found the benefit was not fully explained by how much weight people lost — only about a third of it tracked with waist-circumference reduction — which points to protective effects on the cardiovascular system beyond the scale.
Kidney protection
The FLOW trial (3,533 adults with type 2 diabetes and chronic kidney disease, using the 1.0 mg diabetes dose) was stopped early for efficacy. Semaglutide cut the risk of major kidney events — kidney failure, large sustained drops in kidney function, kidney or cardiovascular death — by 24% (hazard ratio 0.76, p=0.0003). It also reduced cardiovascular events by 18% and death from any cause by 20% in that population.
If you read Posts 2A and 2B, that pattern should look familiar. The SGLT2 inhibitors protect the heart and kidneys too. These are the two drug classes that earned a different level of respect from me — not because they’re weight loss tools, but because they change hard outcomes.
Liver disease — the newest chapter
This is the development that pushed me to write the post now. In April 2025, the ESSENCE trial was published in the New England Journal of Medicine: 1,197 patients with biopsy-confirmed MASH (metabolic dysfunction-associated steatohepatitis — the inflammatory, scarring form of fatty liver disease) and moderate-to-advanced fibrosis, randomized to semaglutide 2.4 mg or placebo.
At 72 weeks, 62.9% of the semaglutide group achieved resolution of steatohepatitis with no worsening of fibrosis, versus 34.3% on placebo. And 36.8% showed improvement in liver fibrosis with no worsening of the inflammation, versus 22.4% on placebo. Liver enzymes fell 30–40% relative to placebo.
On the strength of that, in August 2025 the FDA granted accelerated approval to Wegovy for adults with noncirrhotic MASH and moderate-to-advanced fibrosis — the first GLP-1 ever approved for a liver indication. Two honest caveats I won’t bury: it’s an accelerated (conditional) approval based on interim data, with the confirmatory readout not due until 2029; and the fibrosis benefit, while real, was modest in absolute terms. It’s a genuine milestone, not a cure. Tirzepatide is being studied for the same disease (the SYNERGY-NASH trial) with encouraging results, but as of now semaglutide is the one with the approval.
A word on safety, before anyone accuses me of cheerleading
This post is deliberately the case for these drugs, with the full cost analysis coming in Post 4. But I’m not going to list a wall of benefits and pretend the safety column is blank, because it isn’t. A few things every patient should know going in:
- The whole class carries an FDA boxed warning — the most serious kind — for thyroid C-cell tumors, based on rodent studies. Human relevance is still unknown, but these drugs are contraindicated if you or your family have a history of medullary thyroid carcinoma or MEN 2 syndrome.
- Pancreatitis and gallbladder disease (gallstones) have both occurred in trials and warrant prompt attention if symptoms show up.
- Gastrointestinal side effects — nausea, vomiting, constipation — are common, usually worst during dose escalation, and are the main reason people stop.
None of that erases the benefits below. It’s the normal price of admission for a powerful drug, and it’s why “coordinate with your prescribing physician” isn’t boilerplate — it’s the actual instruction. The deeper cost conversation, including the muscle issue and what happens when you stop, is Post 4.
The honest accounting
So here’s the ledger on the upside, stated plainly:
- Substantial, reproducible weight loss — 15% with semaglutide, up to 22.5% with tirzepatide. No lifestyle-only intervention reliably produces those numbers at that scale.
- Cardiovascular protection — proven in a non-diabetic population, and not fully explained by weight lost.
- Kidney protection — meaningful, in the population that needs it most.
- Liver benefit — now FDA-recognized for MASH with fibrosis.
- Glycemic control — comparable to or better than many older agents, without the hypoglycemia risk of insulin or sulfonylureas, because the insulin effect is glucose-dependent.
That is a serious drug class. I’m not going to pretend otherwise to protect a contrarian brand. When the evidence is this strong, saying so is the honest position.
And now the part I actually care about most
Here’s where my coaching voice comes in, and it’s the same message I’ve carried through this entire series: these drugs are a bridge, not a destination.
A GLP-1 will quiet your appetite. It will not teach you how to eat. It will not build you a single pound of muscle — in fact, left unmanaged, it takes muscle with the fat. It will not give you the training habit, the protein habit, or the relationship with food that keeps the weight off when you eventually come off the drug. And most people do come off, whether by choice, cost, or side effects.
What the drug buys you is a window. A period where the biological screaming of appetite is turned down far enough that you can actually build the things that last: a resistance-training practice that defends your muscle, a protein intake that gives your body the raw material to hold that muscle, and eating patterns that will still be there when the injection isn’t. Used that way — as a bridge you’re actively building across — these drugs are one of the best tools we’ve ever had. Used as a substitute for the work, they buy you a temporary number on a scale and a hard fall when you stop.
The muscle-loss issue, the rebound after discontinuation, the cost, and the exact framework for using a GLP-1 intelligently — that’s Post 4. I’m not going to rush it, because it’s the most important coaching conversation in this whole series.
The bottom line
The cultural narrative on GLP-1s swings between “miracle” and “cheating,” and both are lazy. The truth: these are remarkably effective drugs with real, proven benefits well beyond weight — heart, kidney, and now liver — and a serious catch underneath the weight loss that almost nobody talks about honestly. They work best not as a replacement for nutrition and training, but as a bridge that makes the nutrition and training finally possible.
If you’re on one, or considering one, that framing is the whole game. Come back for Post 4, where we talk about the costs and exactly how to use these drugs without losing the muscle you can’t afford to lose.
Educational content, not medical advice. Every drug has potential side effects, and no medication replaces the work of proper nutrition and training — it accompanies it. Do not start, stop, or change any medication based on a blog post. Bring this framework to your prescribing physician.
Next in the series — Post 4: GLP-1 Receptor Agonists Part 2: The Costs. Lean mass loss, discontinuation rebound, the price problem, and the smart-use framework.
One BadAss BITCH 